Latest Posts

CG Capital, the Leader in Branded Residences in Thailand, Marks Milestone Success for InterContinental Residences Bangkok Asoke Amid Global Economic Uncertainty

Tue, 30 Jun 2026 09:00:21 +0700

Reaffirming Thailand's status as a world destination for the luxury residences market

BANGKOK, THAILAND - Media OutReach Newswire - 30 June 2026 - CG Capital Advisory Limited (CG Capital), Thailand's leading investment manager from Central Group specializing in real estate and hospitality investment, today announced a major strategic investment milestone under the leadership of Mr. Phoom Chirathivat, Managing Partner and Co-Founder of CG Capital. The company unveiled its forward-looking vision for the luxury residential and hospitality markets in Thailand, alongside the official launch of the sales gallery for InterContinental Residences Bangkok Asoke. The project carries a total development value of THB 5.5 billion, with two-bedroom units starting from THB 44.8 million. Reservations have already surpassed 60% ahead of the project's official public launch, a clear sign of confidence in CG Capital's strategy and its world-class standards.CG Capital's Vision: Reading Global Volatility, Positioning Thailand as a World Destination.

InterContinental Residences Bangkok Asoke Building Head

Mr. Phoom Chirathivat, Managing Partner and Co-Founder of CG Capital, said that despite a difficult global economic backdrop, marked by slowing markets, geopolitical conflict, and volatility in traditional capital markets, CG Capital sees Thailand's luxury real estate market moving in the opposite direction. Driving this is a major shift in the behaviour of the world's wealthiest individuals: a wave of global wealth migration. Data from Henley & Partners shows the number of high-net-worth individuals (HNWIs) relocating globally has surged from 51,000 in 2013 to 142,000 in 2025, a 178% increase over 12 years.

Mr. Phoom Chirathivat, Managing Partner and Co-Founder of CG Capital

"Global markets are slowing down, but Thailand is holding its position as a world destination. Demand from HNWI buyers, both Thai and international, hasn't dropped off. If anything, these buyers have become more selective about the assets they choose. That tracks with what we're seeing from Thailand's Board of Investment, which has approved Long-Term Resident visas for more than 6,000 wealthy global citizens since 2022. Thailand isn't just a tourism destination anymore. It's become a place HNWIs choose for long-term residence and investment," said Mr. Phoom.

Claiming the Asian Crown: The "Right Brand, Right Partners, Right Product" Strategy

Rising demand for high-end residences has pushed CG Capital's investment strategy toward branded residences, the fastest-growing segment of the market. Thailand currently holds the largest market share of branded residences in Asia at 23.3% of the region's USD 26.6 billion total market value, ahead of the Philippines (17.3%) and South Korea (11.6%). CBRE's Global Branded Residences report ranks Thailand 4th in the world by number of projects, with Bangkok and Phuket sitting among the world's top 10.

Mr. Phoom Chirathivat added:"The success of InterContinental Residences Bangkok Asoke comes down to understanding global trends. What sets us apart is 'Right Brand, Right Partners, Right Product,' paired with Bangkok's best location, Sukhumvit. We're not chasing a trend. We're reading the market and building on the long-term confidence we have in this country."

From Private Equity DNA to World-Class Product Development

What sets CG Capital apart, as the largest private equity fund manager in Thailand's real estate and hospitality sector, is the way it applies institutional investment thinking to every part of development. Long-term asset value gets weighed through two lenses at once: capital appreciation and living experience.

CG Capital's Next Steps and the Official Sales Gallery Launch

Looking ahead, Mr. Phoom said CG Capital will keep pursuing new investment opportunities in the hospitality segment, setting new standards for Thailand's real estate industry. "Reservations above 60% so far are a clear vote of confidence in CG Capital. Now that the sales gallery is open to the public, we're confident the design and craftsmanship on display will help the project move quickly toward its sales target, further cementing CG Capital's position as Thailand's leading branded residences developer," he said.

InterContinental Residences Bangkok Asoke welcomes visitors to view show units at the sales gallery from 4–5 July onward. Interested parties may schedule an exclusive private appointment via https://residencesasoke.com/
or Tel: 092-989-2616

Expanding the Reach: Bringing the Project to International Buyers

Alongside the sales gallery opening in Bangkok, CG Capital continues to take InterContinental Residences Bangkok Asoke directly to international buyers. The project will next be featured at "Thailand: A New Chapter Begins," an exclusive showcase hosted by CBRE Thailand in collaboration with Taiwan Sotheby's International Realty in Taipei on 3 – 4 July 2026, from 1:30 p.m. – 5:00 p.m. at W Taipei (Strategy Room 1).

Taiwan is a market CG Capital sees as a promising source of long-term residence demand. According to CBRE Thailand and Real Estate Information Center (REIC), Taiwanese buyers now rank as the fourth-largest group of foreign buyers in Thai property market, with transaction value growing an average of 27% a year between 2023 and 2025. Thailand's appeal to this group comes down to geographic proximity, competitive entry pricing, and a lifestyle suited to long-stay living.

For CG Capital, the event is also a chance to read first-hand how Taiwanese HNWIs are thinking about long-term residence and investment in Thailand. Interested parties in Taiwan may get in touch, please contact Taiwan Sotheby's International Realty 0800.887.288 (Taiwan) or CBRE Thailand +66(0) 81 742 6624 (Thailand).

Hashtag: #CGCapital #InterContinentalResidencesBangkokAsoke

The issuer is solely responsible for the content of this announcement.

About CG Capital

CG Capital Advisory Limited manages private equity investments for blue-chip domestic and international institutional and UHNW investors with an inaugural fund size of THB 10 billion, investing primarily in Thailand's hospitality, tourism, and real estate sectors through greenfield, brownfield, and turnaround strategies. Its diversified portfolio includes hotels, branded residences, condominiums, amusement and water parks, and mixed-use developments, focusing on Thailand's leading travel destinations such as Bangkok, Phuket, Koh Samui, and Pattaya.

Led by Mr. Phoom Chirathivat, Managing Partner and Co-Founder of CG Capital, the firm combines deep expertise in investment and hospitality with a strong conviction in Thailand's tourism potential—particularly within the luxury and lifestyle segments.

Legal disclaimer
Sixteen Residences Limited, being the current owner and developer of InterContinental Residences Bangkok Asoke, is solely responsible for the development, marketing, and sale of the Units. The Units are not owned, developed or sold by InterContinental Hotels Group PLC or its affiliates (collectively "IHG"). There exists no joint venture, partnership, ownership or similar relationship between Sixteen Residences Limited and IHG. IHG is not responsible for the content presented in this press release.

FastMed HK Welcomes Greater Bay Area Visitors to Access Doctor Assessment and Prescription Dispensing Services in Hong Kong

Tue, 30 Jun 2026 09:00:20 +0700

HONG KONG SAR - Media OutReach Newswire - 30 June 2026 - FastMed HK, a Hong Kong online dispensing platform, has announced its continued focus on supporting Hong Kong residents and Greater Bay Area visitors who require more convenient access to doctor assessment and prescription dispensing services in Hong Kong. The platform aims to address common pain points in traditional healthcare journeys, including long waiting times, inconvenient access to prescription medicines and privacy concerns, particularly for users seeking support in weight management, women's health, men's health, fertility preparation and other prescription-based healthcare needs.

Online Dispensing Model Addresses Access and Privacy Pain Points

As cross-border travel and healthcare enquiries continue to increase across the Greater Bay Area, some users are looking for a more structured way to understand Hong Kong's prescription medicine system. FastMed HK said its service is designed to provide a clear pathway from online doctor assessment to e-prescription and dispensing, rather than direct self-purchase of prescription medicines.

The platform's model combines online medical assessment, electronic prescription support, medicine delivery and in-store collection. By moving part of the healthcare journey online, FastMed HK aims to reduce unnecessary waiting time and repeated physical visits, while maintaining doctor involvement in prescription decisions.

Doctor Assessment Before Prescription Dispensing

FastMed HK provides online doctor assessment with no consultation fee. After assessment by a doctor, eligible users may receive an electronic prescription and arrange dispensing through delivery or in-store collection. The company emphasises that prescription medicines should only be supplied after professional medical review and according to each user's individual medical situation.

"Medical convenience should not come at the expense of safety, compliance or privacy," FastMed HK said. "Our role is to provide a structured online pathway where users can receive doctor assessment, obtain an electronic prescription where clinically appropriate, and arrange prescription dispensing through a transparent Hong Kong channel. This is particularly relevant for Greater Bay Area users seeking legitimate access to Hong Kong medical resources and professional support."

Supporting Greater Bay Area Users Seeking Hong Kong Medical Access

FastMed HK said the service is also intended to support Greater Bay Area visitors who come to Hong Kong and require doctor assessment before arranging prescription dispensing. The platform noted that some medicine categories may be less accessible, less familiar or more difficult to enquire about in certain markets, creating demand for clear information and regulated medical processes in Hong Kong.

For users travelling to Hong Kong, the platform offers an online-first process that allows them to make enquiries, complete medical assessment where appropriate, and arrange prescription dispensing before collecting medicines in Hong Kong or receiving delivery, subject to the applicable service arrangement.

Service Scope Covers Multiple Prescription-Based Health Needs

FastMed HK's service scope covers a range of prescription-based healthcare categories, including weight management, men's health, women's health, contraception-related enquiries, fertility preparation, obstetric-related medication support, hair-loss management and selected prescription medicine dispensing services.

The platform states that all prescription-related services are subject to doctor assessment. Medicines are dispensed according to applicable Hong Kong medical and pharmacy requirements, and are not intended for self-diagnosis or self-medication without professional advice.

Privacy-Focused Workflow for Sensitive Health Needs

Privacy is another key issue addressed by the platform. For health needs involving sexual health, contraception, hair loss, body weight, fertility preparation or other sensitive personal concerns, some users may delay seeking help due to embarrassment, time constraints or concerns over disclosure.

FastMed HK said its online workflow, discreet communication and dispensing arrangements are designed to offer a more private experience while keeping medical decisions under doctor supervision. The company believes this is especially important for users who require professional support but prefer to avoid unnecessary exposure during the consultation and medicine collection process.

Hashtag: #FastMed #Medical #Health

Wechat: Fastmedhk

The issuer is solely responsible for the content of this announcement.

About FastMed HK

FastMed HK is a Hong Kong online dispensing platform providing online doctor assessment, electronic prescription support and prescription medicine dispensing arrangements. Its service areas include men's health, women's health, fertility preparation, weight management and selected prescription medicine categories. All prescription medicines are subject to doctor assessment and are not intended for self-medication without professional advice.

Contact
Website: https://www.fastmedhk.com/
Telephone: 3596 3984
WhatsApp: 5115 3354

Batmobile Racing Unveils Bold New Livery with Fasoul & Lightec Partnership for Lamborghini Super Trofeo Asia at Fuji Speedway

Mon, 29 Jun 2026 22:38:19 +0700

Championship leaders Tregurtha & Cecotto aim to extend advantage in Pro class aboard the striking new-liveried Car #3

OYAMA, Japan, June 29, 2026 (GLOBE NEWSWIRE) -- Batmobile Racing is proud to announce a landmark dual partnership with premium brands Fasoul and Lightec, debuting a striking new livery for the upcoming round of the renowned Lamborghini Super Trofeo Asia series at the iconic Fuji Speedway in Japan. The team enters this round as the championship leaders in the highly competitive Pro category, with drivers William Tregurtha (United Kingdom) and Jonathan Cecotto (Monaco) at the wheel of the formidable Car #3.

A Partnership Built for Victory
The new collaboration with Fasoul and Lightec represents a significant milestone for Batmobile Racing, uniting three brands with a shared passion for performance, precision, and excellence. The partnership will be proudly displayed across the Car #3 Lamborghini Huracán Super Trofeo EVO2, adorned in a stunning and eye-catching livery that reflects the identity and values of all three partners.

The new livery is set to turn heads in the paddock and on track, combining Batmobile Racing's bold aesthetic with the distinctive branding of Fasoul and Lightec. Fans and motorsport enthusiasts can look forward to seeing the spectacular design at full speed around the legendary curves of Fuji Speedway, set against the breathtaking backdrop of Mount Fuji.

Championship-Contending Driver Line-Up
William Tregurtha, hailing from the United Kingdom, has demonstrated exceptional pace and racecraft throughout the season. A measured and technically skilled racer, Tregurtha's consistency behind the wheel has been a cornerstone of the team's championship charge.

Jonathan Cecotto, representing the Principality of Monaco, brings with him the flair and raw speed that have made him a fan favourite. Racing with an aggressive yet calculating style, Cecotto has been instrumental in securing the points tally that sees Batmobile Racing perched atop the Pro class standings.

Leading the Championship Charge
Batmobile Racing currently sits at the top of the Lamborghini Super Trofeo Asia Pro category standings, a testament to the seamless synergy between drivers, engineers, and the broader team structure. With Fuji Speedway representing a critical juncture in the season, the squad is focused and determined to extend its advantage over the chasing pack.

The Lamborghini Super Trofeo Asia series is widely regarded as one of the most competitive and prestigious one-make championships in the Asia-Pacific region, attracting top-tier talent and elite teams from across the globe. Every point earned is hard-fought, making Batmobile Racing's championship lead all the more impressive.

Team & Driver Quotes
“This partnership with Fasoul and Lightec is a proud moment for everyone at Batmobile Racing. To have two outstanding brands join us at this stage of the season, when we are leading the championship, speaks volumes about the direction this team is heading. The team is fully focused on delivering strong results at Fuji.”
— Batmobile Racing Team Manager, Iris

“Jonathan and I have worked incredibly hard to get ourselves into this championship-leading position, and it is great to have Fasoul and Lightec on board for this round. Fuji Speedway is a legendary venue and we are absolutely fired up to perform. The goal is simple — keep winning.”
— William Tregurtha, Car #3 Driver

“This is a very exciting moment for the team and for us as drivers to get out on track at Fuji. . It is a circuit that rewards commitment and the Super Trofeo EVO2 is a fantastic car to drive there. It is also exciting to have Fasoul and Lightec alongside us this weekend. We head to Japan as championship leaders and that is a position we intend to defend with everything we have.”
— Jonathan Cecotto, Car #3 Driver

Event Information
Series: Lamborghini Super Trofeo Asia
Venue: Fuji Speedway, Japan
Team: Batmobile Racing
Car Number: #3
Category: Pro Class
Drivers: William Tregurtha (GBR) & Jonathan Cecotto (MON)
Partners: Fasoul & Lightec
Championship Position: 1st Overall — Pro Category

Trina Solar Named 2026 Fortune Tech 50 for the Second Year

Mon, 29 Jun 2026 22:37:13 +0700

SHANGHAI, June 29, 2026 (GLOBE NEWSWIRE) -- June 25, Fortune officially released its 2026 Technology 50 list. Trina Solar has been recognized on the ranking again, attribute to its continued innovation and breakthroughs across the solar and energy storage sectors.

The editorial team specifically mentioned Trina Solar as the first photovoltaic and energy storage company listed on the STAR Market to cover four major business segments: PV products, energy storage, integrated systems, and digital energy services. Trina Solar has achieved 41 world records in technological innovation, maintaining a leading position in the industry.

Trina Solar’s self-developed next-gen THBC (TOPCon-compatible Hybrid Back-contact Cell) solar cells achieved a peak efficiency of 28.00%, marking the industry's first time breaking through the 28.0% efficiency bottleneck on a 210R large-area cell. In energy storage, Trina Solar has achieved full-stack self-development and manufacturing capabilities covering battery cells, battery cabinets, and complete energy storage systems.

Trina Solar is actively advancing the large-scale commercialization of TOPCon 3.0 technology, creating a Dual-Engine Model by both TOPCon 3.0 and THBC. These technologies are designed to support more than 85% of global bifacial utility-scale PV applications. Meanwhile, rapidly industrialized THBC for monofacial applications, leveraging its higher front-side power output to deliver greater value to customers.

Also, Trina Solar has achieved a conversion efficiency of more than 35% for small-area perovskite/crystalline silicon tandem cells. Its large-area 210mm perovskite/crystalline silicon tandem solar cell has reached a world-leading efficiency of 32.6%. Trina Solar’s tandem PV module output has surpassed 907W, and its high-efficiency perovskite/crystalline silicon tandem PV modules have secured the first commercial order from a premium distributed energy customer worldwide — marking the first time China’s tandem PV technology has entered the global high-end residential market.

In addition, Trina Solar is advancing its vision of Electricity–Computing Synergy, leveraging integrated solar and storage solutions and grid-forming energy storage technologies to enable intelligent coordination between energy resources and computing power. The company is building end-to-end capabilities spanning green electricity generation to AI-powered green computing, and has established an integrated business model combining direct renewable energy supply, multi-level energy storage, power-computing synergy, computing infrastructure, and computing operations.

Trina Solar has launched a comprehensive AIDC Integrated Solution and successfully deployed the world’s first high-altitude, zero-carbon computing-power demonstration project in Qinghai, China with the partners. Meanwhile, Trina Solar developed an energy storage project in Romania, creating a benchmark case for the future replication of large-scale energy storage projects. The project will help improve local renewable energy integration and grid flexibility, enhance energy security, and strengthen the resilience of the energy system.

In the first quarter of 2026, Trina Solar's revenue increased by 17.4% year-over-year, achieving positive operating cash flow of 4.1 billion yuan. Multiple institutions believe that the Trina Solar's leading position in PV and storage industry is solid. According to InfoLink statistics, by 2025, the company's module shipments will rank among the top three globally, and its tracking mounting system business will rank among the top two globally; distributed systems and digital energy services are growing rapidly and have excellent profitability.

Looking ahead, Trina Solar will continue to place innovation at the core of its development, maximizing the value of integrated solar and storage smart energy solutions and bringing greater Trina strength to the global efforts to combat climate change and enhance energy security.

New Absorb Software Report Shows AI Ambition in L&D Outpacing Organizational Readiness, Signaling a Leadership Moment for Learning

Mon, 29 Jun 2026 22:36:27 +0700

Survey of global learning professionals reveals a widening disconnect between AI goals and execution, underscoring the need for learning to lead enterprise AI adoption

CALGARY, Alberta, June 29, 2026 (GLOBE NEWSWIRE) -- Absorb Software, the leading global learning technology company, today released its AI in Learning Report, revealing a growing disconnect between ambition and organizational readiness as AI adoption continues to accelerate across the enterprise. Based on a survey of more than 1,700 learning professionals, the research shows that while enabling personalization at scale is the top goal for AI in L&D (25%), more than a quarter of organizations have yet to adopt AI in learning at all, and many lack the strategic foundations needed to move beyond experimentation.

The findings highlight a field in transition. Learning teams increasingly view AI as a path to more personalized, scalable experiences, yet adoption remains uneven and narrowly applied. Resistance from stakeholders, limited influence in AI decision-making, and weak alignment with business outcomes continue to slow progress. As AI becomes part of everyday work, the gap between ambition and readiness is placing new pressure on L&D teams to help organizations turn AI investment into real results.

The report explores how L&D teams are navigating AI today, including their goals for personalization and efficiency, the barriers slowing progress, limited representation in enterprise AI strategy discussions, and widespread uncertainty around ethics and governance. Taken together, the findings point to a shift in how organizations will achieve AI success, with greater emphasis on building the capabilities, confidence, and leadership needed to support performance over time.

Key Findings: The State of AI in Learning

Personalization is the top ambition, but it's pointed in the wrong direction: One quarter of L&D teams cite personalization at scale as their primary AI goal. However, the most common use cases today are content creation (30%) and research support (21%), which improve efficiency but fall short of delivering adaptive, outcome-driven learning experiences. Fewer than 4% of respondents say improving overall business performance is their main AI objective, revealing a gap not just between ambition and execution, but between what L&D is optimizing for and what the business actually needs.
AI adoption is becoming increasingly divided: While 46% of organizations have started using AI in learning recently and another 27% have used it for years, 27% have not tried it at all, and of those non-users, 36% say they likely never will. Rather than steady, universal adoption, organizations are splitting into a majority moving ahead and a persistent group of long-term laggards, increasing the risk of widening capability and productivity gaps.
L&D faces resistance while lacking strategic influence: Despite being central to workforce development, L&D teams are included in organizational AI strategy discussions only 22% of the time. At the same time, resistance from stakeholders is the most cited barrier to AI adoption in learning, named by 37% of respondents, creating a cycle where learning teams are expected to enable AI without the authority to shape its direction.
A readiness gap is widening between ambition and execution: While 73% of L&D professionals use AI for basic tasks like drafting and ideation, only 28% feel confident integrating it into real learning workflows without quality degradation. This gap shows that surface-level adoption is outpacing the organizational readiness needed to deliver real performance outcomes.
Ethics and organizational readiness remain weak points: Only 15% of learning professionals feel prepared to manage the ethical implications of AI in learning, despite AI's growing influence on skills development and performance evaluation. An additional 12% cite a lack of internal AI expertise as their primary challenge, reinforcing that many barriers to progress sit at the enterprise level, not within L&D teams themselves.

Learning as the Engine of Intentional AI Adoption
These findings show that many organizations are approaching AI adoption tactically rather than strategically. While experimentation is increasing, long-term value remains constrained by governance gaps, misaligned use cases, and limited organizational readiness. Absorb is built to close that gap, giving organizations the intelligent learning infrastructure they need to move from scattered experimentation to sustained capability and measurable business outcomes.

That gap is exactly what Absorb built Absorb Aura to close. Launched in May 2026, Aura is the agentic AI engine behind Absorb's learning system, coordinating specialized AI agents that connect every learning moment to a measurable business outcome. Rather than adding another point tool, Aura gives organizations the infrastructure to move from scattered experimentation to sustained capability.

"AI has already helped HR and L&D move faster, but speed was never the goal. The real value is helping people build new capabilities that keep the business ahead of change, and that only happens when learning evolves to guide, coach, and adapt to how people actually work and learn." Cheryl Yuran, Chief Human Resources Officer, Absorb Software.

To access the full report, visit AI in Learning Report 2026.
To learn more about Absorb Aura, visit Absorb Aura.

About Absorb Software
Absorb Software is the leading global learning technology company that drives the business forward. Trusted by more than 3,800 organizations and 37 million learners worldwide across customer, partner, and employee audiences, Absorb is the only system that connects workforce readiness to business outcomes. With Aura as its AI intelligence layer, Absorb gets smarter with every interaction, and is the learning system enterprises can rely on and the readiness system their business cannot run without. For more information, please visit absorblms.com.

Bitget Launches Third Year of Anti-Scam Month with New Report on Multi-Asset Fraud

Mon, 29 Jun 2026 22:35:21 +0700

VICTORIA, Seychelles, June 29, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has launched the third year of its Anti-Scam Month initiative with the release of its Anti-Scam Report 2026 titled “The Evolution of Fraud in the Multi-Asset Era”, developed in partnership with blockchain security firm SlowMist. As digital finance expands across cryptocurrencies, tokenized assets, stocks, CFDs, wallets, and AI-powered investment tools, the report examines how fraud is adapting to changing investor behavior and increasingly interconnected financial ecosystems.

The report finds that changes in user behavior are reshaping how fraud campaigns are designed and deployed across digital finance. According to Bitget Research, the share of active users participating across two or more asset classes grew from under 1% in mid-2025 to more than 10% by May 2026. As users move across a wider range of products and platforms, fraud campaigns are increasingly blending multiple narratives, social engineering tactics, AI-generated content, and multiple communication channels within a single operation.

Drawing on Bitget Research and investigations conducted by SlowMist, the report found that many successful scams no longer rely on a single point of compromise. Fraud operators guide victims through a sequence of interactions spanning social media platforms, messaging applications, investment communities, phishing infrastructure, and wallet activity before assets are ultimately stolen. Between July 2025 and June 2026, Bitget's security infrastructure intercepted more than 150 million malicious requests, identified over 13,000 high-risk malicious IP addresses, handled 18,135 user protection cases, and supported the recovery of $32.3 million linked to security incidents and fraudulent activity.

“Security challenges evolve alongside markets. As more users participate across crypto, stocks, tokenized assets and AI-powered products, fraud campaigns are becoming sophisticated in how they build trust and influence decision-making. Understanding those risks is an important step toward protecting users and strengthening confidence across the broader ecosystem,” said Gracy Chen, CEO of Bitget.

The report identifies several trends shaping the current fraud environment, including AI-generated investment personas, deepfake-enabled scams, voice-cloning attacks, synthetic investment communities, wallet-draining operations, malicious smart contracts, and increasingly sophisticated phishing campaigns. Among the cases examined are a deepfake investment scam impersonating Cypriot President Nikos Christodoulides, an AI-generated investment advertising campaign that reportedly defrauded thousands of Swedish investors, the Truman Show synthetic community scam involving approximately 90 fabricated investor identities, and the Rublevka Team wallet-draining operation documented in early 2026.

Beyond examining how scams operate, the report explores victim psychology, common scam entry points, post-theft asset movement, and recovery challenges. It also outlines practical measures users can take to strengthen account security, recognize AI-enabled deception, evaluate investment opportunities more effectively, and respond to security incidents.

Since launching Anti-Scam Month in 2024, Bitget has worked with security researchers, ecosystem partners, and industry organizations to improve awareness around emerging threats and promote stronger user protection practices. Throughout June, Bitget's Anti-Scam Month campaign will feature educational content, security awareness initiatives, and collaborations with industry partners aimed at helping users identify emerging threats and strengthen their ability to protect digital assets.

For more information, please read the report here.

About Bitget
Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

Securonix Appoints Toby Weiss as Chief Executive Officer to Scale the Next Era of AI-Powered Security Operations

Mon, 29 Jun 2026 22:34:45 +0700

Veteran cyber security and enterprise software executive to accelerate the industry's transition from alert-driven security operations to AI-powered execution.

MELBOURNE, Australia. 30th June 2026 — Securonix, Inc., a six-time Leader in the Gartner® Magic Quadrant™ for SIEM, today announced the appointment of Toby Weiss as Chief Executive Officer.

Weiss joins Securonix at a defining moment for security operations. Security teams across highly regulated industries, including healthcare, financial services, energy, and government, as well as managed security service providers (MSSPs), face growing threat volumes, increasingly sophisticated attacks, mounting compliance requirements, and persistent talent shortages. At the same time, organisations are under pressure to improve security outcomes while controlling operational costs and maximising the value of their security investments.

As organisations modernise their SOCs, they are increasingly seeking platforms that deliver deeper threat visibility, stronger analytics, greater operational efficiency, and measurable outcomes. Securonix is uniquely positioned to address these priorities through its Unified Defense SIEM platform, combining industry-leading analytics, intelligent data management through Data Pipeline Manager (DPM), and Agentic AI capabilities that help security teams operate faster, more effectively, and at a greater scale.

As Chief Executive Officer, Weiss will lead Securonix through its next phase of growth and innovation. Under his leadership, the company will continue advancing its vision for the future of security operations while maintaining a relentless focus on customer outcomes. Securonix will accelerate innovation across its Unified Defense SIEM platform, helping enterprises and MSSPs improve detection efficacy through advanced analytics, expand visibility while optimising costs with DPM, and increase SOC productivity through Agentic AI capabilities such as Sam, the AI SOC Analyst, and Agentic Mesh. The company's focus remains clear: helping customers strengthen security operations, improve efficiency, and achieve measurable business value from their cyber security investments.

"Toby brings a powerful combination of cyber security expertise, enterprise software leadership, and operational excellence," said Nadeem Syed, Executive Chairman of the Securonix Board and Senior Managing Director at Vista Equity Partners. "Security operations are at an inflection point as organisations move from alert-driven tools toward AI-powered execution. Toby has spent his career scaling businesses through pivotal technology transitions, and we are confident in his ability to lead Securonix forward."

Weiss brings more than three decades of experience leading enterprise software and cyber security businesses. Most recently, he served as Chief Executive Officer of Fiery, the leader in AI-powered cloud workflow and high-speed digital front-end solutions for the industrial imaging and print industry, where he led the company through strategic growth, operational expansion, and its successful acquisition by Seiko Epson Corporation. Earlier in his career, Weiss served as President and Chief Executive Officer of Application Security, Inc., a pioneer in database security, and held senior executive leadership positions at CA Technologies, where he led global security software businesses serving many of the world's largest enterprises. Weiss has successfully scaled organisations, expanded customer adoption, improved operational performance, and led businesses through major technology transitions.

"Security operations are entering a new era where success will be measured not by how many alerts analysts review, but by how much security work organisations can execute," said Weiss. "Our customers want three things: better security outcomes, greater operational efficiency, and the ability to scale without proportionally increasing costs. Securonix is uniquely positioned to deliver on those priorities. Our advanced analytics help organisations identify the threats that matter most. Our Data Pipeline Manager gives customers greater control over security data economics and visibility. Our Agentic AI innovations help automate and accelerate investigation and response workflows while maintaining governance and human oversight. Together, these capabilities enable organisations to operate more effectively today while preparing for the future of AI-powered security operations."

“Customers are looking for measurable security outcomes despite growing operational complexity,” said Marion Smith, Chief Financial Officer at Securonix. “They want to improve analyst productivity, accelerate investigations, strengthen security posture, and maximise the value of their security investments. Toby understands how to connect innovation with customer success and business results. His leadership will help accelerate growth, deepen customer partnerships, and continue delivering the operational outcomes security teams need.”

Securonix will continue advancing its Unified Defense SIEM platform, including innovations such as Sam, the AI SOC Analyst, and Agentic Mesh, helping security teams automate repetitive work, accelerate investigations, improve response effectiveness, and increase SOC efficiency while maintaining governance and human oversight.

Through innovations such as Data Pipeline Manager, which can reduce SIEM data costs by 30-50%, and Agentic AI capabilities that can accelerate investigations by 50-80%, Securonix is helping organisations achieve faster time to value, improve security outcomes, and maximise ROI from their cyber security investments.

About Securonix
Securonix is transforming security operations with the industry’s first Unified Defense SIEM with Agentic AI, built to decide and act across the threat lifecycle with a human-in-the-loop philosophy. Its cloud-native platform unifies detection, investigation, and response, while enabling Sam, the AI SOC Analyst, and a productivity-based AI operating model for the SOC, so organisations can measure and govern AI by the analyst work it delivers. Helping enterprises become Breach Ready and Board Ready, Securonix delivers accountable, outcome-driven security operations at scale. Recognised as a Leader in the Gartner® Magic Quadrant™ for SIEM and a Customers’ Choice by Gartner Peer Insights™, Securonix delivers trusted security operations for global enterprises. Learn more at www.securonix.com

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Mon, 29 Jun 2026 22:33:43 +0700

Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.
The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.

The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia for treatment-resistant depression (“TRD”), an indication for which regulated patient access is available. TRD refers to major depression that has not responded to multiple standard antidepressant treatments and represents a significant unmet medical need.

"We are proud to be among the few Nasdaq-listed companies commercially supplying psilocybin to patients with treatment-resistant depression outside of clinical trials," said Dane Stevens, CEO and Co-Founder of Optimi. "Our medicine is produced start to finish in Canada and shipped to pharmacy partners globally, and we are seeing expanding reimbursement coverage from both private and public insurers. We believe Australia is providing an early model for how naturally derived psilocybin can be safely prescribed for TRD in real-world practice, and we are not aware of any serious adverse events reported since inception based on data collected through December 31, 2025."

Australia became the first country in the world to recognize psilocybin as a medicine, rescheduling it from a prohibited substance to a controlled medicine for the treatment of TRD, effective July 1, 2023. MDMA was rescheduled for the treatment of post-traumatic stress disorder on the same day, and Optimi manufactures both psilocybin and MDMA. Patients have since gained broader access under an updated Authorized Prescriber framework that expanded therapist eligibility and treatment settings, as detailed in the Company’s news release dated May 29, 2026.

Under the Therapeutic Goods Administration’s Authorized Prescriber Scheme, Optimi’s psilocybin is being prescribed to patients in Australia and reimbursed by both public and private payers, including the Department of Veterans’ Affairs, the National Disability Insurance Scheme, WorkCover, and Medibank. More than 750 clinicians have been trained to deliver the therapy, and the Company is not aware of any serious adverse events that have been reported under the scheme after more than two years of regulated commercial use.

The exported capsules were produced start to finish in-house at Optimi’s wholly owned GMP facility in Princeton, British Columbia, Canada, under its Health Canada Drug Establishment Licence, and shipped under export authorization issued by Health Canada. Optimi is among a small number of GMP-licensed manufacturers supplying naturally derived psilocybin to the Australian market, where recurring orders contribute to commercial revenue for the Company.

Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, in support of both patient access and clinical research. Inquiries regarding product for special access programs and clinical trial supply may be directed to sales@optimihealth.ca.

About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

Mon, 29 Jun 2026 22:31:46 +0700

Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period
Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, Canada

PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the study, patients reported clinically meaningful improvements in skin symptoms (itch, flaking, and redness) and body temperature regulation as early as week 4, with improvements in sleep and health-related quality of life (HRQoL) starting at week 12. Improvements were sustained throughout the study period, with additional gains in HRQoL reported through week 48.

“Cutaneous T-cell lymphoma can affect far more than just the skin, impacting how patients feel and function every day,” said Professor Julia Scarisbrick, Principal Investigator, Honorary Professor of Dermatology, University Hospitals Birmingham NHS Foundation Trust. “These findings from the PROSPER study are encouraging because they show that in patients with MF or SS, mogamulizumab can help ease symptoms that affect everyday life, and those improvements can be long-lasting.”

Mycosis fungoides and Sézary syndrome are two sub-types of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that primarily affects the skin, presenting as patches, plaques, tumors, or reddening of the entire skin, and may be associated with severe itching. The disease may spread to lymph nodes, blood, and/or other organs in some patients.

“Clinical studies are stronger when they are shaped by the voices and lived experiences of people living with the disease,” said Susan Thornton, study author and co-CEO, Cutaneous Lymphoma Foundation. “Collaboration between industry and the patient community is essential to designing studies that generate more relevant insights into symptom burden, quality of life, and the day-to-day treatment experience.”

Key PROSPER Findings

The study included 73 patients with relapsed or refractory MF or SS (n=41 MF; n=32 SS). Patient-reported outcomes were collected at baseline and throughout the study using:

A CTCL-specific symptom diary assessing the severity of skin itch, pain, redness, and flaking, frequency of sleep problems, and difficulty regulating body temperature
The MF/SS-CTCL-QoL questionnaire, which measured the impact of CTCL on daily life
The Brief Fatigue Inventory (BFI), which assessed fatigue severity and its impact on daily functioning

Mean symptom scores (mean +/- standard deviation) improved from baseline to week 48 across key skin symptoms, including itch (−2.5 ±3.4), flaking (−3.1 ±3.5), redness (−3.1 ±3.5), and pain (−1.7 ±4.4). Clinically meaningful improvements in skin itch, flaking, and redness were observed as early as week 4, and improvements in pain by week 12 (i.e., exceeding the minimum important difference (MID)). These effects were sustained through week 48.

By week 48, 30% of patients reported at least a 2-point improvement in sleep, and 37% reported better body temperature regulation. Patients also showed significant, clinically meaningful improvements in disease-specific health-related quality-of-life scores (MF/SS-CTCL-QoL) beginning at week 12, with further gains through week 48. While fatigue scores changed little among patients with MF, patients with SS showed a significant improvement in total BFI scores, reaching the MID threshold at week 48.

“Studies like PROSPER show why real-world data generation matters, particularly in rare cancers like mycosis fungoides and Sézary syndrome,” said Angela Williams, PhD, Global Head of Health Economics and Outcomes Research at Kyowa Kirin. “These data help broaden understanding of the lived experience of patients and care partners with mogamulizumab treatment in everyday practice, including the impact on symptoms and quality-of-life that may not be fully reflected by outcomes collected in clinical trial.”

About PROSPER

The objective of the PROSPER (ClinicalTrials.gov ID NCT05455931) study is to gain insight into the experiences of patients with MF or SS receiving mogamulizumab in real-world clinical practice through the collection of patient-reported outcomes (PRO) data, enriched with qualitative data on disease and treatment experience. The study was designed with input from patients and caregivers to ensure patient-relevant outcomes were selected, and it was conducted in six countries across North America, Europe, and the Middle East, at 19 sites working with patients with MF or SS. Patients were followed for up to 50 weeks from study enrollment.

U.S. POTELIGEO (mogamulizumab-kpkc) Indication

POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.

Infections: Monitor patients for signs and symptoms of infection and treat promptly.

Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.

Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information in full Prescribing Information as well as Patient Information.

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

Flash Sports & Media, Holdings Inc. (NASDAQ: FLZH) Announces Lanka Premier League 2026 Schedule; Vijay Shankar–Moeen Ali’s Kandy Royals Face Dambulla Sixers as Defending Champions Jaffna Kings Open Against Galle Gallants

Mon, 29 Jun 2026 22:31:05 +0700

Sinhala commentary and a globally stacked player pool set the stage for LPL’s strongest regional and international season yet

Innovative Production Group FZ, LLC (“IPG”), a subsidiary of Flash Sports & Media Holdings, confirms a July 17–August 8 window for the league’s sixth edition; expanded Sinhala-language commentary and more than 650 overseas registrations from 21 countries underscore growing global reach

COLOMBO, Sri Lanka, June 29, 2026 (GLOBE NEWSWIRE) -- Flash Sports & Media Holdings, Inc. (NASDAQ: FLZH) (“Flash” or the “Company”) today announced the confirmed fixtures for the Lanka Premier League (LPL) 2026, which the Company expects to be its biggest and most connected season to date. The sixth edition will run from July 17 to August 8, 2026, opening under lights at Colombo’s Sinhalese Sports Club Cricket Ground, where defending champions Jaffna Kings — captained by Sri Lanka’s Bhanuka Rajapaksa and powered by Bangladesh all-rounder Shakib Al Hasan — begin their title defense against Dasun Shanaka’s Galle Gallants.

The opening weekend shifts quickly into another marquee contest as Indian international Vijay Shankar and England white-ball star Moeen Ali lead the Kandy Royals against the Dambulla Sixers on July 18. Across three weeks of competition, five franchises will contest a double round-robin league stage before the playoffs in Colombo — a structure the Company believes reflects both the league’s growing international standing and Sri Lanka’s continued ability to attract top-tier cricketing talent.

LPL 2026 brings together one of the strongest line-ups in the competition’s history. The Kandy Royals headline with Shankar, Moeen, Angelo Mathews and Wanindu Hasaranga, while Jaffna Kings retain a formidable championship core featuring Shakib, Taskin Ahmed, Rajapaksa and Dunith Wellalage. Fans can also look forward to James Neesham, Dushmantha Chameera, Eshan Malinga, Kusal Mendis, Kamindu Mendis, Rahmanullah Gurbaz and several emerging Sri Lankan talents.

That global appeal has continued to grow, with more than 650 overseas registrations received from 21 countries ahead of this season’s player-selection process. Alongside that international momentum, LPL 2026 plans to place a stronger emphasis on deepening its roots at home through expanded Sinhala-language commentary and broader regional fan-engagement initiatives.

The league is organized by Sri Lanka Cricket, with commercial rights managed by Innovative Production Group FZ, LLC (“IPG”), a subsidiary of Flash. Mr Anil Mohan Sankhdhar, Founder and CEO of IPG, said: “LPL’s growth has always been built on two priorities — creating a world-class cricket product and ensuring it remains closely connected to fans across Sri Lanka and the region. This season reflects that vision. We expect the international interest we continue to receive, combined with stronger regional accessibility and fan-first experiences, toposition the league for another significant step forward.”

Among the marquee league-phase fixtures, the Kandy Royals and Jaffna Kings meet twice in five days, potentially setting up contests involving Shankar, Moeen, Hasaranga and Shakib, alongside heavyweight clashes such as Colombo Kaps versus Kandy Royals and Dambulla Sixers versus Jaffna Kings.

The five franchises — Colombo Kaps, Dambulla Sixers, Galle Gallants, Jaffna Kings and Kandy Royals — will compete in a double round-robin league stage, after which the top four teams advance to the playoffs in Colombo. Qualifier 1 and the Eliminator will be held on August 5, followed by Qualifier 2 on August 7, with the Lanka Premier League 2026 Final scheduled for August 8 at the R. Premadasa Stadium.

Lanka Premier League 2026 — League Stage Fixtures

July 17 — Jaffna Kings vs Galle Gallants (Colombo)
July 18 — Kandy Royals vs Dambulla Sixers (Colombo)
July 18 — Galle Gallants vs Colombo Kaps (Colombo)
July 19 — Dambulla Sixers vs Jaffna Kings (Colombo)
July 19 — Colombo Kaps vs Kandy Royals (Colombo)
July 21 — Dambulla Sixers vs Kandy Royals (Dambulla)
July 22 — Jaffna Kings vs Colombo Kaps (Dambulla)
July 22 — Dambulla Sixers vs Galle Gallants (Dambulla)
July 23 — Kandy Royals vs Colombo Kaps (Dambulla)
July 23 — Galle Gallants vs Jaffna Kings (Dambulla)
July 25 — Galle Gallants vs Kandy Royals (Dambulla)
July 25 — Dambulla Sixers vs Colombo Kaps (Dambulla)
July 26 — Kandy Royals vs Jaffna Kings (Dambulla)
July 26 — Galle Gallants vs Dambulla Sixers (Dambulla)
July 28 — Colombo Kaps vs Jaffna Kings (Kandy)
July 29 — Galle Gallants vs Kandy Royals (Kandy)
July 29 — Colombo Kaps vs Dambulla Sixers (Kandy)
July 30 — Jaffna Kings vs Kandy Royals (Kandy)
August 1 — Colombo Kaps vs Galle Gallants (Kandy)
August 2 — Jaffna Kings vs Dambulla Sixers (Kandy)

Playoffs — R. Premadasa Stadium, Colombo

August 5 — Qualifier 1 — 15:00 (R. Premadasa Stadium, Colombo)
August 5 — Eliminator — 19:30 (R. Premadasa Stadium, Colombo)
August 7 — Qualifier 2 — 19:30 (R. Premadasa Stadium, Colombo)
August 8 — Final — 19:30 (R. Premadasa Stadium, Colombo)

About Flash Sports & Media Holdings, Inc.

Flash Sports & Media Holdings, Inc. (Nasdaq: FLZH) is a cricket-focused sports and media company seeking to develop and commercialize cricket media, league-management, sponsorship, and related sports-entertainment opportunities. Through its relationship with Innovative Production Group FZ, LLC, Flash is focused on professional cricket properties, media and broadcast opportunities, sponsorships, league operations, and related commercial initiatives. The Company's business plans remain subject to execution risks, market conditions, definitive agreements, third-party approvals, and the Company's ability to finance, develop, and commercialize its sports and media initiatives. https://flashsportsandmedia.com

Bitdeer Technologies Group Signs Colocation Lease Agreement for Tydal, Norway AI Data Center Site

Mon, 29 Jun 2026 22:29:47 +0700

SINGAPORE, June 29, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) ("Bitdeer" or the "Company"), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced that its wholly-owned subsidiary, Tydal Data Center AS, has executed a colocation lease agreement (the "Lease") for its Tydal, Norway AI data center site. The Lease has not yet become effective and remains subject to the satisfaction of certain conditions precedent beyond Bitdeer's control, including the completion of certain external customer and supplier arrangements by the counterparty. There is no assurance that such conditions will be satisfied, or that the Lease will become effective.

"Signing this agreement marks an exceptional step in Bitdeer's execution of its global AI infrastructure strategy," said Haris Basit, Chief Strategy Officer of Bitdeer. "We look forward to sharing comprehensive details of this transaction, including terms and strategic context, once the Lease has become effective."

Bitdeer intends to provide a public announcement, including details regarding the commercial terms and expected business impact of the Lease upon its effectiveness, which is expected within the next month.

About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for AI and Bitcoin mining infrastructure. Bitdeer is committed to providing comprehensive Bitcoin mining solutions for its customers and building AI computational infrastructure to support the AI revolution. Bitdeer handles complex processes involved in computing such as equipment procurement, transport logistics, data center design and construction, equipment management, and daily operations. Bitdeer also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed data centers across multiple countries, including the United States, Norway, Bhutan, and Ethiopia. To learn more, visit https://ir.bitdeer.com/ or follow Bitdeer on X@Bitdeer and LinkedIn @Bitdeer.

Zymeworks to Acquire Theravance Biopharma, Inc.

Mon, 29 Jun 2026 22:28:57 +0700

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio
Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk
Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growth
Transaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI® profit share from OMERS Life Sciences, and Theravance Biopharma’s expected net cash balance of $360 million at closing. Zymeworks will contribute $219 million of cash at close and expects to receive $100 million TRELEGY ELLIPTA® milestone in Q1 2027, assuming milestone conditions met, offsetting cash outlay
Acquisition adds diversified assets beyond YUPELRI®, including additional royalty interests, milestone payments, a preclinical I&I portfolio, and $2.5 billion in Irish tax attributes, further strengthening both potential near-term cash flow generation and long-term development optionality
Continued execution of Zymeworks share repurchase program for up to $125 million of common shares reflects ongoing capacity and intent to deploy capital for future buybacks
Conference call with Zymeworks management today at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference® in people’s lives. This proposed acquisition adds YUPELRI®, the first and only nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), to Zymeworks’ partnered portfolio, furthering the Company's commitment to improving outcomes for patients with serious diseases.

YUPELRI® is positioned to add near-term commercial cash flows for Zymeworks upon closing, alongside existing Ziihera® (zanidatamab-hrii) cash flows, supporting a disciplined, and self-sustaining capital allocation model in which proceeds are reinvested to further advance our internal research and development portfolio, acquire additional partnered assets, and return capital to shareholders. Unlike traditional royalty business models, which are generally limited to passive participation, Zymeworks’ differentiated approach enables the acquisition and active restructuring of businesses to generate royalty-like economics with greater control, strategic flexibility, and a clear focus on long-term value creation. Zymeworks’ differentiated model, pairing an efficient internal infrastructure with diversified cash flows, uniquely positions the Company to capitalize on the value of Theravance Biopharma’s business.

YUPELRI® adds an anticipated long-duration and potentially growing cash flow stream

This acquisition, when closed, provides Zymeworks with access to a 35% U.S. net profit share in YUPELRI®, the only approved nebulized LAMA for the maintenance treatment of COPD.
YUPELRI® has been marketed in the United States since 2019 through a collaboration between Viatris Inc. (“Viatris”) and Theravance Biopharma, who are responsible for U.S. community and hospital promotion respectively.
Full-year U.S. net sales of YUPELRI® in 2025 were $266.6 million, representing 12% growth over 2024. For the first quarter of 2026, U.S. net sales of YUPELRI® were reported as $62.4 million, representing 7% growth over the same quarter in 2025.
Settlements have been reached with all YUPELRI® generic filers for an April 2039 licensed launch date for their versions of the product, or earlier depending on certain circumstances.
Theravance Biopharma remains eligible to receive an additional $125 million in commercial milestone payments from Viatris based upon U.S. net sales, as well as double-digit tiered royalties and additional milestones on ex-U.S. net sales.

Potential upside from other Theravance Biopharma portfolio assets

In addition to YUPELRI®, Theravance Biopharma is expected to receive $100 million in commercial milestone payments from Royalty Pharma in Q1 2027 related to global net sales of TRELEGY ELLIPTA® by GSK.
Theravance Biopharma is eligible to receive up to ~20% royalty on net sales of VIBATIV® (telavancin) from Cumberland.
Following close of the transaction, Zymeworks will retain ownership of Theravance Biopharma’s research and development assets, which will be evaluated in the context of the Company’s broader pipeline and capital allocation framework.
Zymeworks will explore the opportunity to externalize acquired assets. During the one-year period from closing of this transaction, a designee of Theravance Biopharma will seek to potentially license, divest or otherwise monetize ampreloxetine, with no additional resources expected from Zymeworks. The economics of any such transaction will be shared 20/80 between Zymeworks and Theravance Biopharma shareholders.
In addition, Zymeworks will retain approximately $2.5 billion of Irish tax attributes accumulated by Theravance Biopharma for potential future utilization.

Upon closing, Zymeworks intends to complete Theravance Biopharma’s previously announced organizational restructuring to align its resources with its commercial focus on YUPELRI®, which is expected to significantly reduce research and development expenses and general and administrative costs, as well as seek additional synergies in the cost structure of the combined entities. Zymeworks intends to substantially preserve existing hospital promotion infrastructure from Theravance Biopharma’s commercial organization.

“The acquisition of Theravance Biopharma represents successful execution of one of the key strategic priorities we outlined earlier this year,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “We are building a more diversified and durable business by combining partner-driven cash flows and innovative R&D, together in an integrated strategic approach to build long-term stockholder value. Upon closing, this acquisition meaningfully expands and diversifies future revenue sources for our partnered product portfolio, with an expected near-term impact on commercial royalty revenue. This transaction also aligns with our mission to combine near-term patient access with long-term innovation, by leveraging cash flows from established medicines to fund development of next-generation therapies, supporting both patients receiving treatment today and those awaiting future breakthroughs. YUPELRI® addresses a critical need for the approximately 16 million Americans living with COPD, and we look forward to supporting continued access to this important therapy with Viatris.”

“We are pleased to partner with Zymeworks in the execution of its strategy to integrate royalty growth, internal innovation, and strategic acquisitions to maximize long-term value. For OMERS, our financing aligns well with our mandate to deliver steady long-term returns to our more than 665,000 members,” said Rob Missere, Managing Director and Head of Life Sciences, OMERS Life Sciences.

Terms of the Transaction
Under the terms of the agreement, Zymeworks will acquire all the outstanding equity of Theravance Biopharma for $17.00 per share, which represents a total transaction value of approximately $929 million in cash consideration subject to customary adjustments, which is payable at closing.

The transaction has been unanimously approved by the boards of directors of both companies and is subject to customary closing conditions, including receipt of certain regulatory approvals and approval by Theravance Biopharma shareholders. The transaction is expected to close in the second half of 2026.

The transaction is expected to be accounted for as a business combination. The purchase price is expected to be primarily allocated to identifiable intangible assets, including YUPELRI® and contractual royalty streams, with any residual value recorded as goodwill. Potential milestone receipts will be evaluated as part of the purchase accounting process and recognized in accordance with applicable accounting standards. Zymeworks expects to provide additional details on the purchase price allocation upon closing of the transaction.

Kirkland & Ellis LLP is serving as legal counsel to Zymeworks. Matheson provided Irish tax counsel to Zymeworks. TD Cowen served as a financial advisor to Zymeworks on the OMERS royalty note. MTS Health Partners provided financial advice to Zymeworks.

Lazard is serving as lead financial advisor to Theravance Biopharma. Evercore is also serving as financial advisor to Theravance Biopharma. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel to Theravance Biopharma.

Sidley Austin LLP is serving as legal counsel to OMERS Life Sciences. Maples and Calder (Ireland) LLP and Davies Ward Phillips & Vineberg LLP provided Irish legal counsel and tax counsel, respectively, to OMERS Life Sciences.

Financing of the Transaction
The acquisition will be financed through a $350 million non-dilutive, non-recourse note from OMERS Life Sciences, in which 75% of the YUPELRI® profit-share cash flows are contractually assigned to OMERS to service the associated debt obligations. The non-recourse note is secured by assets and entities of Theravance Biopharma related to YUPELRI® and do not have any recourse to the remainder of the Zymeworks’ business. This non-recourse note is structured to preserve the Company’s balance sheet flexibility and minimize shareholder dilution.

In addition, approximately $219 million of existing cash resources of Zymeworks will be used to finance the remaining purchase price of the transaction, along with expected net cash balances of Theravance Biopharma of approximately $360 million at closing. Factoring in the $100 million milestone payment expected from Royalty Pharma in Q1 2027 related to sales of TRELEGY, Zymeworks’ effective net investment is expected to be reduced by roughly 50%.

Zymeworks 2026 Share Repurchase Program
On May 14, 2026, the Board of Directors of Zymeworks authorized a share repurchase program under which the Company may repurchase up to $125 million of its outstanding common stock, par value $0.00001 per share. As of June 29, 2026, the Company has repurchased 1,437,073 shares of common stock for $35.4 million (exclusive of commission expense and estimated excise tax), representing an average purchase price of $24.63 per common share. Zymeworks plans to continue executing the share repurchase program, reflecting its ongoing capacity and intent to deploy capital toward future buybacks.

Investor Call Details
Zymeworks invites investors and the general public to view and listen to a live webcast of its conference call with investment analysts at 8:30 am ET on Monday, June 29, 2026.

Dial-in details and webcast link are available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations. A webcast replay of the call will be available on the Zymeworks website within 24 hours following the conclusion of the live call and will be archived for a limited period.

About Theravance Biopharma, Inc.
Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with COPD. The Company is committed to creating/driving shareholder value.

YUPELRI® is an inhalation solution, a long-acting muscarinic antagonist (LAMA) and the first and only once-daily nebulized bronchodilator approved for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. COPD is the third leading cause of death and the fourth leading cause of hospital readmissions in the U.S., affecting approximately 16 million Americans.

About OMERS Life Sciences and OMERS
OMERS Life Sciences provides royalty financings and other non-dilutive solutions to biopharma companies and academic institutions.

OMERS is a jointly sponsored, defined benefit pension plan, with more than 1,000 participating employers ranging from large cities to local agencies, and more than 665,000 active, deferred and retired members. Our members include union and non-union employees of municipalities, school boards, local boards, transit systems, electrical utilities, emergency services and children’s aid societies across Ontario. OMERS teams work in Toronto, London, New York, Amsterdam, Luxembourg, Singapore, Sydney and other major cities across North America and Europe – serving members and employers, and originating and managing a diversified portfolio of high-quality investments in government bonds, public and private credit, public and private equities, infrastructure and real estate.

About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

EMGA Secures USD 15 Million Senior Debt Facility for CDB

Mon, 29 Jun 2026 22:27:58 +0700

LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP (EMGA) announced the successful closure of a USD 15 million senior debt facility for Citizens Development Business Finance PLC (CDB), marking a significant milestone in strengthening Sri Lanka’s financial sector and supporting sustainable growth.

This transaction underscores EMGA’s continued commitment to Sri Lanka, while reinforcing CDB’s vision of expanding access to finance for SMEs and advancing its green portfolio. The facility was arranged in collaboration with Swedfund, Sweden’s development finance institution, which plays a pivotal role in promoting sustainable economic development across emerging markets.

Commenting on the transaction, CDB’s MD/CEO Mahesh Nanayakkara stated, “This financing strengthens our ability to empower SMEs and accelerate our green initiatives, ensuring that CDB continues to play a leading role in shaping Sri Lanka’s sustainable financial future.”

Emphasising the strategic importance of the debt finance, Head of Investment Banking and Managing Director at EMGA Sajeev Chakkalakal said, “We are pleased to close this latest transaction and ensure CDB’s continued vision of supporting SMEs and its green portfolio in Sri Lanka, while simultaneously helping expand Swedfund’s ongoing operations in the region.”

Reflecting on the broader impact, Head of Operations and Managing Director at EMGA Jeremy Dobson noted: “Following several challenging years for Sri Lanka, EMGA has moved swiftly to capitalise on improving local conditions, strengthening CDB’s funding base and diversifying its sources of capital.”

Björn Areskog, Investment Director at Swedfund, said, “We invest to increase access to capital to support the ability of MSMEs to grow, create more local jobs, add tax revenues and increase affordable access to products and services.”

Citizens Development Business Finance PLC (CDB): A leading non-bank financial institution in Sri Lanka, listed on the Colombo Stock Exchange, recognised for its focus on sustainable finance, digital innovation, and SME empowerment.

Swedfund is Sweden’s development finance institution (DFI), wholly owned by the Swedish government, with a mandate to reduce poverty and promote sustainable economic development in emerging markets. Swedfund provides long-term financing in the form of equity, loans, and technical assistance, primarily targeting sectors such as financial institutions, energy, and sustainable enterprises. The organisation places strong emphasis on environmental, social, and governance (ESG) standards, aiming to create lasting development impact while supporting responsible and inclusive business growth.

Emerging Markets Global Advisory LLP (EMGA), with offices in London and New York, helps financial institutions and corporates seeking new debt or equity capital. EMGA’s multinational team combines decades of experience necessary to complete transactions on behalf of its clients within the world’s emerging markets and frontier economies, including Sri Lanka, which remains a key market. With a proven track record in capital formation and strategic advisory throughout diverse economic cycles, EMGA is solidifying its position as one of the pre-eminent niche investment banks focused on emerging and frontier markets.

Introducing Circeus: The AI-Native Holding Company and Announcing New Equity Financing

Mon, 29 Jun 2026 22:25:18 +0700

The group behind Shop Circle launches Circeus as its holding company brand, backed by a new equity investment from the EBRD. Shop Circle continues as the group’s retail and commerce software division. The investment will accelerate the deployment of AI across the portfolio and fund the continued acquisition of the software businesses that power the everyday economy.

LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Circeus, the AI-native holding company for mission-critical software, today announced its launch alongside an equity investment from the European Bank for Reconstruction and Development (EBRD), with participation from other investors.

The launch introduces Circeus as the group's holding company brand, reflecting the broader B2B software portfolio the group now operates with AI embedded throughout. The investment will help scale the group’s central AI engineering capability and support continued acquisitions.

The AI-native holding company
Circeus has completed 18 acquisitions over the last four years and serves more than 200,000 businesses worldwide. The group is scaling profitably and is adding more revenue this year than in the previous two years combined, with further acquisitions expected to complete over the coming months.

From strategy to results
Over the past three years, AI has moved from experimentation to scaled deployment across the portfolio. Today, this is visible in performance:

Double-digit share of net new bookings driven by AI-enabled features
Up to ~80% customer experience automation in several products
100%+ improvements in developer productivity through AI-assisted workflows

These outcomes are consistent across multiple businesses, demonstrating a repeatable model that improves product performance, operational efficiency and post-acquisition EBITDA, rather than isolated successes.

A compounding model, with AI as the operating system
Circeus grows through a repeatable model: selectively acquiring software businesses and connecting them to a central AI capability, with agents and skills built once and deployed across the portfolio. Post-acquisition, Circeus embeds AI into products, automates operations, and reuses infrastructure, data, and insights across the group.

Each improvement compounds, creating a structural advantage difficult for standalone software businesses to replicate. AI is not a layer added on top of each product; it is the operating system of the group, moving software from systems of record to systems of action, and turning tasks into outcomes.

A permanent home for founders
Founders who sell to Circeus get a permanent home for their business: brands, teams, and customer relationships are preserved, while the group brings AI engineering, growth expertise, and centralised back-office support.

What they said
“As AI evolves software from passive tools into systems that act and execute, the addressable market for technology is expanding several-fold. We are building the platform to capture this shift. We were not running a fundraising process, as we are profitable and well capitalised, but we chose to make space for EBRD given their institutional standing and to lean further into a market that presents several attractive opportunities,” said Luca Cartechini, Founder and CEO of Circeus.

“Across different businesses, we have proven that evolving a product into its AI-native form can drive a step-change in the market it can address. The hard part is doing this repeatedly, and that is what we have built: a central engineering capability that turns each transformation into a foundation for the next,” said Gian Maria Gramondi, Founder and COO of Circeus.

“With more than $220m of total capital raised to date, we have substantial firepower to deploy in a highly attractive acquisition environment, with several deals expected to complete over the coming months. Deal after deal, we are proving a repeatable operating model that drives EBITDA uplift and strong returns across the assets we acquire and operate,” said Robin Hardt, CFO of Circeus.

“We are backing a team bringing AI to the essential software that businesses across our regions rely on every day, and Circeus’s compounding model aligns closely with EBRD’s long-term mandate. The market for bringing AI to the real economy is enormous, and we look forward to supporting Circeus, alongside a strong group of investors, across the journey,” said Bruno Lusic, Investor at EBRD.

EBRD’s long-term perspective aligns with Circeus’s approach to building compounding platforms over decades, not quarters. The investment brings the group’s total equity raised to more than $120m and total capital raised to more than $220m, with backing from NFX, QED Investors, Nextalia, 645 Ventures, 3VC, Endeavor Catalyst, CDP Venture Capital, alongside a $100m+ credit facility from i80 Group.

Looking ahead

Despite the pace of AI innovation, adoption across the real economy remains early. Only around one in five enterprises in Europe and the US currently report using AI. [1]

Circeus exists to help close the AI adoption gap by embedding frontier capabilities into the mission-critical software that businesses depend on. The everyday economy runs on software that moves goods, powers commerce and supports specialist industries. Circeus believes AI compounds most where domain knowledge runs deepest, making vertical software, with its proprietary workflows and data, central to the group’s portfolio.

The next generation of platforms will execute work, not just provide tools, and that shift is already underway.

About Circeus
Circeus is the AI-native holding company for mission-critical software. The group acquires and evolves vertical software businesses that power the everyday economy, embedding AI through its central engineering team to move software from systems of record to systems of action. Circeus operates from London, Milan and Sarajevo. Shop Circle, its commerce software division, serves retailers, wholesalers and brands worldwide.

About EBRD
The EBRD is one of the world’s leading multilateral development banks, with a portfolio of approximately €62 billion and more than €220 billion invested since 1991 across over 7,800 projects. The Bank also has dedicated equity capabilities, supporting private-sector growth, innovation and sustainable development across its regions.

Memperkenalkan Circeus: Perusahaan Induk Berbasis AI dan Pengumuman Pendanaan Ekuitas Baru

Mon, 29 Jun 2026 22:24:29 +0700

Grup di balik Shop Circle meluncurkan Circeus sebagai merek perusahaan induknya, didukung oleh investasi ekuitas baru dari EBRD. Shop Circle terus beroperasi sebagai divisi perangkat lunak untuk ritel dan perdagangan milik grup. Investasi ini akan mempercepat penerapan AI di seluruh portofolio perusahaan sekaligus mendanai akuisisi berkelanjutan atas berbagai bisnis perangkat lunak yang mendukung kegiatan ekonomi sehari-hari.

LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Circeus, perusahaan induk berbasis AI yang berfokus pada perangkat lunak penting bagi kelangsungan operasional, hari ini mengumumkan peluncurannya sekaligus perolehan investasi ekuitas dari European Bank for Reconstruction and Development (EBRD), dengan partisipasi dari sejumlah investor lainnya.

Peluncuran ini memperkenalkan Circeus sebagai merek perusahaan induk grup, yang mencerminkan portofolio perangkat lunak B2B yang kini semakin luas dan dioperasikan dengan integrasi AI secara menyeluruh. Investasi ini akan membantu meningkatkan skala kapabilitas rekayasa AI terpusat milik grup serta mendukung keberlanjutan akuisisi.

Perusahaan induk berbasis AI
Dalam empat tahun terakhir, Circeus telah menyelesaikan 18 akuisisi dan melayani lebih dari 200.000 bisnis di seluruh dunia. Grup ini terus tumbuh secara menguntungkan, dan pada tahun ini, tambahan pendapatannya lebih besar daripada total tambahan pendapatan dalam dua tahun sebelumnya. Sejumlah akuisisi lainnya juga diperkirakan akan rampung dalam beberapa bulan mendatang.

Dari strategi menuju hasil
Dalam tiga tahun terakhir, penerapan AI telah beralih dari tahap eksperimen menuju implementasi berskala luas di seluruh portofolio. Saat ini, hasil penerapannya terlihat pada kinerja:

Fitur berkemampuan AI menghasilkan porsi dua digit dari nilai kontrak baru bersih
Tingkat otomatisasi pengalaman pelanggan hingga 80% pada beberapa produk
Produktivitas pengembang meningkat lebih dari 100% melalui alur kerja yang didukung AI

Hasil yang konsisten di berbagai bisnis menunjukkan bahwa model tersebut dapat diterapkan secara berulang untuk meningkatkan kinerja produk, efisiensi operasional, dan EBITDA pasca-akuisisi, bukan hanya menunjukkan keberhasilan pada kasus-kasus tertentu.

Model pertumbuhan majemuk, dengan AI sebagai sistem operasinya
Circeus bertumbuh melalui model yang dapat diterapkan secara berulang dengan cara mengakuisisi bisnis perangkat lunak secara selektif dan menghubungkannya dengan kapabilitas AI terpusat. Agen AI dan berbagai kemampuannya dikembangkan satu kali, lalu diterapkan di seluruh portofolio. Setelah akuisisi, Circeus mengintegrasikan AI ke dalam berbagai produk, mengotomatiskan kegiatan operasional, serta memanfaatkan kembali infrastruktur, data, dan wawasan di seluruh grup.

Setiap peningkatan menghasilkan efek majemuk sehingga menciptakan keunggulan struktural yang sulit ditiru oleh perusahaan perangkat lunak yang berdiri sendiri. AI bukan sekadar lapisan tambahan pada setiap produk, melainkan menjadi sistem operasi bagi seluruh grup. AI menggeser peran perangkat lunak dari sekadar sistem pencatatan menjadi sistem yang mampu bertindak dan mengubah tugas menjadi hasil nyata.

Rumah permanen bagi para pendiri
Para pendiri yang menjual bisnisnya kepada Circeus mendapatkan rumah permanen bagi bisnis mereka: merek, tim, dan hubungan dengan pelanggan tetap dipertahankan, sedangkan grup menyediakan kapabilitas rekayasa AI, keahlian dalam mendorong pertumbuhan, serta dukungan fungsi administratif (back-office) yang terpusat.

Apa kata mereka
“AI mengubah perangkat lunak dari alat pasif menjadi sistem yang mampu bertindak dan menjalankan tugas sehingga pasar yang dapat dijangkau oleh teknologi berkembang hingga berkali-kali lipat. Kami membangun platform untuk memanfaatkan perubahan ini. Kami sebenarnya tidak sedang mencari pendanaan karena perusahaan telah mencatatkan keuntungan dan memiliki modal yang memadai. Namun, kami memilih membuka ruang bagi EBRD untuk berinvestasi, mengingat reputasinya sebagai institusi terkemuka, sekaligus meningkatkan fokus kami pada pasar yang menawarkan berbagai peluang menarik,” ujar Luca Cartechini, Pendiri dan CEO Circeus.

“Di berbagai bisnis, kami telah membuktikan bahwa mengembangkan suatu produk menjadi produk berbasis AI dapat mendorong peningkatan signifikan pada pasar yang mampu dijangkaunya. Tantangan sesungguhnya adalah mampu melakukannya secara berulang. Karena itulah kami membangun kapabilitas rekayasa terpusat yang menjadikan setiap transformasi sebagai landasan bagi transformasi berikutnya,” ujar Gian Maria Gramondi, Pendiri dan COO Circeus.

“Dengan total modal lebih dari US$220 juta yang telah diperoleh hingga saat ini, kami memiliki kapasitas pendanaan yang besar untuk dimanfaatkan di tengah peluang akuisisi yang sangat menarik. Sejumlah transaksi juga diperkirakan akan rampung dalam beberapa bulan mendatang. Dari satu transaksi ke transaksi berikutnya, kami terus membuktikan bahwa model operasional ini dapat diterapkan secara konsisten untuk meningkatkan EBITDA dan menghasilkan imbal hasil yang kuat dari setiap aset yang kami akuisisi dan kelola,” ujar Robin Hardt, CFO Circeus.

“Kami mendukung tim yang menghadirkan AI ke dalam perangkat lunak penting yang digunakan setiap hari oleh berbagai bisnis di wilayah kami. Model pertumbuhan majemuk Circeus juga sangat selaras dengan mandat jangka panjang EBRD. Peluang pasar untuk menghadirkan AI ke sektor ekonomi riil sangat besar. Kami berharap dapat terus mendukung Circeus sepanjang perjalanan pertumbuhannya, bersama kelompok investor yang kuat,” ujar Bruno Lusic, Investor di EBRD.

Perspektif jangka panjang EBRD selaras dengan pendekatan Circeus dalam membangun platform dengan model pertumbuhan majemuk dalam hitungan dekade, bukan saja kuartal. Investasi ini meningkatkan total pendanaan ekuitas grup menjadi lebih dari US$120 juta dan total modal yang diperoleh menjadi lebih dari US$220 juta, dengan dukungan dari NFX, QED Investors, Nextalia, 645 Ventures, 3VC, Endeavor Catalyst, dan CDP Venture Capital, serta fasilitas kredit senilai lebih dari US$100 juta dari i80 Group.

Menatap ke Depan
Di tengah pesatnya laju inovasi AI, tingkat penerapannya dalam kegiatan ekonomi riil masih berada pada tahap awal. Saat ini, hanya sekitar satu dari lima perusahaan di Eropa dan AS yang melaporkan telah menggunakan AI. [1]

Circeus hadir untuk membantu mengatasi kesenjangan dalam adopsi AI dengan mengintegrasikan kapabilitas AI termutakhir ke dalam perangkat lunak yang penting untuk kelangsungan operasional yang menjadi andalan berbagai bisnis. Kegiatan ekonomi sehari-hari berjalan berkat perangkat lunak yang menggerakkan distribusi barang, mendukung perdagangan, dan menunjang berbagai industri khusus. Circeus meyakini bahwa AI memberikan manfaat terbesar ketika diterapkan pada bidang yang memiliki pengetahuan domain mendalam. Oleh karena itu, perangkat lunak vertikal (dibuat khusus untuk industri tertentu), dengan didukung alur kerja dan data eksklusif, menjadi inti dalam portofolio grup.

Platform generasi berikutnya tidak hanya akan menyediakan alat, tetapi juga mampu menjalankan tugas, dan pergeseran tersebut kini sedang berjalan.

Tentang Circeus
Circeus adalah perusahaan induk berbasis AI yang berfokus pada perangkat lunak penting bagi kelangsungan operasional. Grup ini mengakuisisi dan mengembangkan perusahaan perangkat lunak vertikal yang menopang kegiatan ekonomi sehari-hari. Melalui tim rekayasa terpusatnya, grup mengintegrasikan AI untuk mengubah perangkat lunak dari sekadar sistem pencatatan menjadi sistem yang mampu mengambil tindakan. Circeus beroperasi dari London, Milan, dan Sarajevo. Shop Circle, divisi perangkat lunak perdagangan Circeus, melayani peritel, distributor grosir, dan berbagai merek di seluruh dunia.

Tentang EBRD
EBRD merupakan salah satu bank pembangunan multilateral terkemuka di dunia, dengan portofolio sekitar €62 miliar. Sejak tahun 1991, EBRD telah menyalurkan investasi lebih dari €220 miliar ke lebih dari 7.800 proyek. Bank ini juga memiliki kapabilitas khusus di bidang ekuitas untuk mendukung pertumbuhan sektor swasta, inovasi, dan pembangunan berkelanjutan di seluruh wilayah operasinya.

Arcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle East

Mon, 29 Jun 2026 22:22:21 +0700

Expansion builds on successful collaboration across Latin America and reinforces commitment to advancing innovative cardiometabolic therapies across international markets

Abu Dhabi, United Arab Emirates and Seoul, South Korea, June 29, 2026 (GLOBE NEWSWIRE) -- Arcera Life Sciences ("Arcera"), a global life sciences company focused on advancing innovative and sustainable healthcare solutions, and Daewoong Pharmaceutical Co., Ltd. ("Daewoong"), a leading South Korean pharmaceutical company, today announced the expansion of their strategic partnership for Enavogliflozin, Daewoong's novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, into key markets across the Middle East.

The agreement builds upon the successful collaboration established between Daewoong and M8 Pharmaceuticals for Latin America, a partnership that became part of the Arcera platform following Arcera's integration of M8 in December 2024. Since then, Arcera and Daewoong have continued to strengthen their relationship, most recently achieving a significant milestone with the approval of Enavogliflozin in Mexico.

The expansion into the Middle East represents the next phase of the partnership and reflects both companies' shared commitment to increasing patient access to innovative therapies for people living with type 2 diabetes and related cardiometabolic conditions across emerging markets.

Enavogliflozin is a novel SGLT2 inhibitor developed by Daewoong and approved in South Korea for the treatment of type 2 diabetes mellitus. The therapy has demonstrated meaningful efficacy in glycemic control and represents an important addition to the growing range of treatment options available to patients and healthcare professionals globally.

Strengthening a Strategic Partnership Across Regions
The partnership expansion highlights Arcera's ability to leverage relationships, capabilities, and expertise across its integrated global platform, creating opportunities beyond the original scope of acquired businesses.

By combining Daewoong's innovative R&D capabilities with Arcera's extensive regulatory, market access, and commercial infrastructure across international markets, the collaboration aims to accelerate access to innovative therapies in regions where patient needs continue to evolve. In the Middle East, cardiometabolic health remains an important healthcare priority and diabetes prevalence is among the highest in the world.

Isabel Afonso, Chief Executive Officer, Arcera said: "At Arcera, we are building a leading life sciences company that connects innovation with patients across international markets. The expansion of our relationship with Daewoong reflects the strength of our business and demonstrates how we can create value by building long-term strategic partnerships that extend across multiple regions and therapeutic areas."

Shawn Park, Chief Executive Officer, Daewoong Pharmaceutical, said: "This expansion reflects the global competitiveness of Enavogliflozin as a next-generation SGLT2 inhibitor. By combining our innovative therapy with Arcera’s proven infrastructure, we aim to address the high prevalence of diabetes in the Middle East and Egypt and deliver a novel treatment option to patients across the region."

The companies will work closely together on regulatory, market access, and commercialization activities to support future launches across the agreed territories, including United Arab Emirates, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain, Egypt and Iraq.

This agreement further reinforces Arcera's strategy of identifying, licensing, and commercializing innovative medicines from leading pharmaceutical and biotechnology companies worldwide and bringing them to patients across high-growth international markets.

About Arcera Life Sciences
Arcera Life Sciences is a global life sciences company headquartered in Abu Dhabi, United Arab Emirates. Our purpose is to enable longer and healthier lives while creating sustainable growth. We develop, manufacture, and commercialize a broad range of innovative and proven medicines in key international markets. With a large footprint reaching patients in over 90 markets, and manufacturing and packaging facilities in eight countries, we offer more than 2,000 medicines across various therapeutic areas worldwide. Arcera was established by ADQ, an Abu Dhabi-based sovereign investor, to realize Emirate's ambition as a global leader in innovative and sustainable healthcare.

To learn more about Arcera, visit www.arceralifesciences.com.

About Daewoong Pharmaceutical Co., LTD.
Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals globally, with in-house R&D capabilities, international operations across Asia and the United States, and strategic partnerships in more than 100 countries worldwide.

Turing Award Laureate Joseph Sifakis Appointed Chief Scientific Advisor as CaoCao Accelerates AI Transformation

Mon, 29 Jun 2026 22:20:53 +0700

HANGZHOU, China, June 29, 2026 (GLOBE NEWSWIRE) -- On June 29, Joseph Sifakis, a world-renowned AI scientist and Turing Award laureate, was formally invited to serve as Chief Scientific Advisor of the CaoCao AI Innovation Center. He will provide core academic support, a global perspective and strategic roadmap guidance for CaoCao’s transformation into an AI-native company.

Professor Sifakis is one of the leading pioneers in trustworthy artificial intelligence and complex systems. He has long focused on the safety, reliability and verifiability of complex intelligent systems, with his research widely applied in safety-critical fields such as aerospace and industrial control. In recent years, Professor Sifakis has concentrated on trustworthy AI and autonomous systems. His research aligns closely with the development needs of Robotaxi and other autonomous driving technologies and will provide world-class theoretical guidance and methodological support for CaoCao in building safe, reliable and verifiable autonomous driving services and a physical AI mobility technology platform.

This appointment marks Professor Sifakis’s first in-depth involvement in shaping the AI strategy of a Chinese technology company.

Shawn Gong, CEO of CaoCao, said that Professor Sifakis’s appointment reflects strong recognition from the international scientific community of CaoCao’s AI development direction and technology roadmap. Supported by world-class academic resources and the advantages of collaboration across industry, academia and research, the company will continue to strengthen its core capabilities in artificial intelligence and autonomous driving, reinforce the foundations of intelligent mobility development, and accelerate the deep integration of AI with future mobility scenarios.

Recently, CaoCao officially launched its full-scale AI transformation and unveiled its new RoboX strategy, with the goal of building a globally leading physical AI mobility technology platform and an intelligent mobility network spanning diverse applications, including Robotaxi and Robovan. Leveraging its full-capability, closed-loop RoboX ecosystem integrating intelligent purpose-built vehicles, intelligent driving technologies and intelligent operations, CaoCao is accelerating the development of capabilities for large-scale autonomous driving operations.

2026 "Encounter Qi, Dreamy Zhaoge" Spring Festival Fair Kicks Off

Mon, 29 Jun 2026 22:20:24 +0700

HEBI, China, June 29, 2026 (GLOBE NEWSWIRE) -- The millennia-old city of Zhaoge welcomed the Spring Festival with grandeur. Zhaoge Old Street in Qi County, Central China’s Henan Province, blazed with lights and teemed with visitors. Amid thundering drums and leaping lion dances, Qi County announced the official opening of the nearly month-long “Encounter Qi, Dreamy Zhaoge” Spring Festival Fair, inviting residents and tourists alike to embark on a 3,000-year cultural journey.

Zhaoge, located in present-day Qi County, served as the capital for the last four kings of the Shang Dynasty (c. 1600–1046 BCE) and later as the capital of the Wei State during the Western Zhou period. Today, it stands among Henan Province's first designated historical and cultural cities and is revered as the cradle of Chinese surname culture.

The highlight came with "Zhaoge: The Enchanted Dance of the Fengshen", a processional immersive performance staged against the backdrop of Zhaoge's storied past. The production recreates the historical moment 3,000 years ago when King Zhou of Shang pacified the Dongyi tribes and unified the Central Plains.

Scattered throughout the street, pop-up performances and NPC character parades animate the ancient thoroughfare, while specialty markets and local delicacies tempt the senses. Visitors can admire murals depicting characters from Investiture of the Gods (Fengshen Yanyi), decode decorative lanterns featuring Shang Dynasty idioms, and purchase Fengshen-themed cultural creative products — all offering a tangible connection to this legendary heritage.

Zhaoge Old Street ranks among Henan's first designated historical and cultural blocks. It is also recognized as a leisure tourism district and a nighttime cultural tourism consumption cluster. Situated at the heart of the ancient city, the street emphasizes historical and cultural industries, integrating traditional heritage into modern tourism scenes. Today, it has become a premier nighttime destination for both locals and visitors.

Mavenir Meraih Penghargaan Mitra Terbaik Tahun Ini dari Deutsche Telekom untuk Inovasi Jaringan Terbaik

Mon, 29 Jun 2026 22:19:04 +0700

Proyek MeeC Diakui Berhasil Menghemat Energi hingga 65% pada Jaringan Inti 5G Milik Deutsche Telekom

BONN, Jerman, June 27, 2026 (GLOBE NEWSWIRE) -- Mavenir, perusahaan perangkat lunak yang membangun jaringan seluler berbasis cloud dan mengintegrasikan AI sejak tahap perancangan, hari ini mengumumkan bahwa pihaknya telah meraih Penghargaan Mitra Terbaik Tahun Ini dari Deutsche Telekom untuk Inovasi Jaringan Terbaik. Penghargaan ini diserahkan langsung oleh jajaran pimpinan senior Deutsche Telekom dalam ajang Telekom Campus Fair 2026.

Pengakuan ini menegaskan peran penting Mavenir dalam inisiatif Most Energy Efficient Core (MeeC), sebuah proyek kolaborasi unggulan bersama Deutsche Telekom yang dibangun dengan Horizontal TelCo Cloud milik Deutsche Telekom sebagai fondasinya. Arsitektur cloud milik Deutsche Telekom ini juga menjadi model rujukan bagi industri telekomunikasi. MeeC telah mendefinisikan ulang efisiensi energi pada jaringan inti 5G dengan menekan konsumsi energi hingga 65% selama periode trafik rendah, sekaligus tetap mempertahankan performa dan kualitas layanan tanpa kompromi.

Diluncurkan pada tahun 2025, MeeC menerapkan analisis trafik canggih berbasis AI serta pengoptimalan beban kerja prediktif untuk mendeteksi dan menghilangkan pemborosan energi di seluruh fungsi Jaringan Inti 5G, tanpa mengorbankan performa jaringan maupun kualitas layanan. Proyek ini menunjukkan bahwa pengurangan konsumsi energi secara signifikan dapat dicapai dalam skala komersial pada jaringan yang beroperasi secara aktif.

Pardeep Kohli, Chief Executive Officer Mavenir, mengatakan, "Meraih Penghargaan Mitra dari Deutsche Telekom merupakan suatu kehormatan besar bagi seluruh tim Mavenir. MeeC merupakan bukti nyata atas berbagai kemungkinan yang terbuka melalui perpaduan arsitektur berbasis cloud, otomatisasi berbasis AI, dan kemitraan yang autentik. Jaringan berkelanjutan bukan lagi sekadar ambisi masa depan, melainkan telah menjadi kenyataan dalam kegiatan operasional. Kami bangga telah membantu Deutsche Telekom membuktikannya dalam skala besar."

Telekom Partner Awards mengapresiasi kontribusi luar biasa para mitra Deutsche Telekom dalam bidang teknologi jaringan, operasional, dan keberlanjutan. Penghargaan tersebut juga diberikan bersama kepada AMD sebagai bentuk pengakuan atas kontribusinya terhadap inisiatif MeeC.

Catatan untuk Editor:

Most energy efficient Core: Presentasi di Mobile World Congress
https://www.youtube.com/watch?v=Mw2g-CSSAtI

Tentang MeeC (Most Energy Efficient Core)
MeeC merupakan program inovasi Deutsche Telekom yang berfokus pada transformasi efisiensi Jaringan Inti 5G melalui otomatisasi cerdas. Pencapaian utama mencakup:

Penghematan energi hingga 65% dibandingkan dengan kondisi operasional dasar
Prediksi trafik berbasis AI dan peningkatan skala secara real time
Konsolidasi beban kerja secara dinamis di seluruh fungsi yang berbasis cloud
Otomatisasi tanpa intervensi manual (zero-touch) yang memungkinkan pengoptimalan secara berkelanjutan
Penerapan yang telah teruji pada jaringan produksi Tier-1 yang beroperasi secara aktif

Tentang Mavenir
Mavenir menghadirkan jaringan cerdas, otomatis, dan dapat diprogram melalui pengembangan solusi perangkat lunak yang mengutamakan telekomunikasi, berbasis cloud, dan mengintegrasikan AI sejak tahap perancangan untuk operator seluler. Keahlian mendalam perusahaan ini di bidang telekomunikasi telah terbukti melalui implementasi bersama dengan lebih dari 300 operator secara global di lebih dari 120 negara, yang secara bersama-sama melayani lebih dari 50% pelanggan di dunia. Mavenir menggabungkan pengalaman telekomunikasinya yang mendalam dengan keahlian cloud dan IT serta keahlian sains data yang sangat penting untuk memecahkan tantangan nyata yang dihadapi pelanggan. Solusi perangkat lunaknya yang telah terbukti mengintegrasikan AI sejak tahap perancangan sehingga membawa masa depan yang sepenuhnya berbasis AI dan membantu operator bertransformasi menjadi perusahaan teknologi. Untuk mendapatkan informasi selengkapnya, kunjungi www.mavenir.com

Hi3D Launches an AI-Powered Workflow for 3D Printing Creators

Mon, 29 Jun 2026 22:18:15 +0700

HONG KONG, June 27, 2026 (GLOBE NEWSWIRE) -- As building-block collectibles, mecha figures, and designer toys gain popularity, more enthusiasts want to create original characters and custom mecha designs. Yet turning an idea into a physical model has long required Blender, CAD tools, mesh repair software, slicers, and advanced fabrication skills.

With its first-anniversary release, Hi3D is introducing an end-to-end AI manufacturing workflow for 3D printing that automates tasks once handled by professional modelers and experienced makers.

From a Prompt to an Original Mecha Design
Inside Hi3D, an original mecha project can begin with a simple text description.

Using a Blokees-style mecha as an example, users enter a character concept and visual description, and Hi3D's Nano-Banana 2 image engine generates concept artwork optimized for 3D reconstruction. The system also supports consistent multi-view generation across the head, torso, limbs, armor, and weapon systems.

For collectors and hobbyists, this removes a major barrier to original character creation: professional illustration skills.

Manufacturing-Ready 3D Models in Two Minutes
Once the artwork is approved, Hi3D's Sparc3D high-precision generation engine reconstructs a complete 3D model in approximately two minutes.

Unlike AI 3D tools focused mainly on visualization, Hi3D generates watertight meshes optimized for physical manufacturing. Structural integrity, topology continuity, and printability are handled automatically, reducing cleanup work that previously took hours to minutes.

Automatic Part Splitting and Connector Generation
For large mecha models, print preparation can be harder than creation itself. Complex characters often must be split into components such as the head, torso, arms, legs, and weapons to fit desktop printer build volumes. Traditionally, this requires manual work inside Blender or CAD software.

Hi3D's intelligent segmentation system automatically analyzes the model and separates it into logical printable components. The platform then generates matching connector structures, including mortise-and-tenon joints and ball-joint assemblies.

Combined with Hi3D's Press-Fit Tolerance system, which calculates assembly clearances based on printer specifications, nozzle size, and material characteristics, printed parts can be assembled directly without extensive trial-and-error testing.

Smart Build Plate Optimization for Printing
After model preparation is complete, Hi3D automatically enters the print setup stage.

The platform's smart build plate optimization system adjusts orientation and support strategies based on model geometry. Character figures prioritize surface quality, while mechanical components focus on reducing support material and shortening print time.

The final result is an enhanced 3MF file compatible with major slicing ecosystems, including Bambu Studio, OrcaSlicer, Creality Print, and Elegoo Slicer, creating a seamless workflow from concept generation to print preparation.

From Idea to Physical Manufacturing
Using this workflow, the time required to transform an original Blokees-style mecha from a text prompt into a printable 3MF file can be reduced to around five minutes.

Beyond efficiency, Hi3D aims to make original mecha creation accessible to a much wider audience. By automating modeling, part splitting, connector generation, and print preparation, workflows once reserved for professionals are becoming available to everyday makers, collectors, and hobbyists.

About Hi3D
Hi3D is an All-in-One AI 3D Maker Platform that connects AI-powered creation with physical manufacturing. The platform combines AI 3D generation, intelligent part splitting, connector generation, tolerance optimization, smart build plate layout, and one-click 3MF export into a single workflow.

As Hi3D celebrates its first anniversary, the company is also preparing to launch Hi3D 3.0, featuring the industry's first 2048³ ultra-high-resolution AI 3D generation. Alongside limited-time subscription offers and creator competitions, early access to the new release will also be available.

New users can receive 300 free Hi3D credits to experience the complete AI-to-3D-print workflow.

Slovenia Merayakan 74 Restoran yang Diakui MICHELIN pada 2026: Hiša Franko Mempertahankan Predikat Tiga Bintang

Mon, 29 Jun 2026 22:17:04 +0700

MICHELIN Guide Slovenia 2026 menampilkan 74 restoran, bertambah dua restoran dibandingkan tahun lalu. Slovenia kini memiliki total 13 bintang MICHELIN, bertambah satu dibandingkan pada 2025.

LJUBLJANA, Slovenia, June 26, 2026 (GLOBE NEWSWIRE) -- Hiša Franko, yang dipimpin Ana Roš, kembali meraih predikat tertinggi yakni tiga bintang MICHELIN, sedangkan Milka Restaurant, di bawah kepemimpinan David Žefran, kembali mendapat dua bintang MICHELIN. Delapan restoran menerima satu bintang MICHELIN, dengan Galerija okusov untuk pertama kalinya tahun ini masuk dalam kategori tersebut. Sebanyak 12 restoran menerima predikat Bib Gourmand. Sebanyak 52 restoran masuk dalam kategori Selected, dengan enam di antaranya merupakan restoran baru.

Tahun ini juga menandai debut MICHELIN Opening of the Year Award di Slovenia. Pengakuan khusus lainnya mencakup Young Chef Award untuk Marko Magajne dari Galerija okusov; Sommelier Award, yang diberikan kepada Nejc Farčnik dari Grič; serta Service Award, yang diberikan kepada Peter Patajc dari Gostilnica Ruj. Opening of the Year Award diberikan kepada Gostilna Francl, yang dipimpin oleh Sebastijan Kovačič.

MSc Maja Pak Olaj, Direktur Badan Pariwisata Slovenia, menekankan: “Hasil MICHELIN Guide Slovenia tahun ini kembali menegaskan bahwa Slovenia semakin memperkuat posisinya sebagai salah satu destinasi gastronomi paling diakui di Eropa. Masuknya 74 restoran dari seluruh penjuru Slovenia menunjukkan bahwa gastronomi berkualitas tinggi kini kian menjadi bagian penting dari pariwisata Slovenia, sekaligus merupakan pendorong utama pengembangan pariwisata dengan nilai tambah yang lebih tinggi. Kemitraan kami dengan MICHELIN turut meningkatkan visibilitas Slovenia di tingkat internasional, mendorong peningkatan standar kualitas, serta memperkuat reputasi para chef dan restoran Slovenia. Kami sangat bangga karena Slovenia menerima Opening of the Year Award untuk pertama kalinya tahun ini, bersamaan dengan Young Chef Award, Sommelier Award, dan Service Award, yang semuanya menunjukkan keunggulan di berbagai bidang gastronomi. Dalam hal jumlah restoran yang diakui MICHELIN per kapita, Slovenia menempati posisi rata-rata di antara negara-negara Eropa yang tercakup dalam panduan tersebut. Hal ini menegaskan kualitas luar biasa dan ambisi besar gastronomi Slovenia. Selamat kepada semua penerima penghargaan. Badan Pariwisata Slovenia akan terus mendukung pengembangan dan promosi internasional Slovenia sebagai destinasi yang menawarkan pengalaman gastronomi istimewa.”

Hainan FTP marks 6-month milestone of special customs operations, signs deals during Hong Kong visit

Mon, 29 Jun 2026 22:01:25 +0700

HONG KONG SAR - Media OutReach Newswire - 29 June 2026 - As the Hainan Free Trade Port (FTP) marked the six-month milestone since the launch of its full special customs operations, a Hainan provincial delegation wrapped up a three-day visit to Hong Kong. During the visit, the delegation signed deepened cooperation agreements with several major local chambers of commerce and promoted the latest policies introduced since the island-wide special customs operations took effect.

CCPIT Hainan signs a deepened cooperation MOU with the Hong Kong General Chamber of Commerce.

According to data released by Hainan Province during the visit, Hainan's foreign trade has surged since the launch of special customs operations. As of June 17, the province's total goods imports and exports reached RMB 173.98 billion (approximately US$24 billion), up 54.6% year on year. Imports of zero-tariff goods hit RMB 2.645 billion, a 120% jump that generated tariff savings of RMB 440 million. A total of 172,100 new market entities were registered—a 61% increase—including 1,240 foreign-invested enterprises. Zero-tariff items now account for 74% of all tariff lines, benefiting more than 12,000 market entities.

During the Hong Kong visit, China Council for the Promotion of International Trade Hainan Provincial Committee (CCPIT Hainan) signed separate deepened cooperation MOUs with the Chinese General Chamber of Commerce, Hong Kong and the Hong Kong General Chamber of Commerce. Under the MOUs, the parties will establish a regular liaison mechanism for the periodic exchange of economic and trade information, and will promote collaboration in areas including professional services, green finance, the digital economy, supply chain management, and cultural tourism. Mutual enterprise service desks will be set up to provide consulting services regarding policies and projects. The parties will leverage their complementary strengths to help Chinese mainland enterprises access overseas markets via Hong Kong, while facilitating Hong Kong companies' entry into the Chinese mainland through Hainan.

The delegation also held talks with the British Chamber of Commerce in Hong Kong and the American Chamber of Commerce in Hong Kong, exploring ways for British and American businesses to leverage Hainan's value-added processing tariff exemptions and multifunctional free trade accounts to position themselves in regional supply chains and cross-border investment and financing. HSBC, De Beers, and other British firms are already active in Hainan, and the UK served as the Guest of Honor country at the 2025 China International Consumer Products Expo.

According to industry analysts, amid the shifting international trade landscape, Hainan is leveraging Hong Kong's "super-connector" role to accelerate its integration with global capital and business networks, while simultaneously offering the Hong Kong business community a policy testing ground for entering the Chinese mainland market.

Hashtag: #CPITHainan

The issuer is solely responsible for the content of this announcement.

World's First Commercial Multimodal LLM for Cultural Tourism Enters Broad Application

Mon, 29 Jun 2026 22:00:21 +0700

XI'AN, CHINA - Media OutReach Newswire - 29 June 2026 - The world's first commercial multimodal large language model (LLM) for cultural tourism, called BoGuan, has entered broad application in Xi'an, China. This model generates commercial returns by supporting the creation of digital IP for intangible cultural heritage, the development of cultural tourism applications, and the improvement of short drama production. This is injecting new momentum into both China's heritage preservation initiatives and the cultural tourism industry.

A visitor tries out the BoGuan-powered AI photography app

Xi'an is one of China's oldest cities and one of its most popular international tourist destinations. Shaanxi Culture Industry Investment Group (SCG) is working with partners like Huawei, China Telecom Shaanxi, and China West Airport Group (CWAG) to promote cultural tourism using digital technologies including AI and 5G-A.For example, BoGuan is used to support a new AI travel companion agent that had been made available to over 4 million users by March of this year.

In September 2025, SCG and Huawei unveiled the BoGuan Large Model, the world's first commercial multimodal LLM for cultural tourism. It is also China's first industry-specific model dedicated to the preservation of cultural heritage. This model is built on intelligent computing infrastructure and a high-quality dataset. The dataset has over 1.2 PB of data, including 31 million images, 4.4 million minutes of video footage, 2.18 million minutes of audio recordings, 510 3D models, and 960 million pieces of structured text.

BoGuan can generate highly-accurate multimodal content, such as museum-quality content about cultural relics. This allows it to support the creation of new digital relic presentations, the digitalization and preservation of traditional craftsmanship, and the creation of digital IP for intangible cultural heritage. Zhang Beiyuan, a dough sculpture artisan, said, "With this model, I can complete a dough sculpture that used to take two or three months in less than a week." BoGuan is also used to create digital IP like the popular cartoon character Tang Biaobiao, which is designed by integrating local cultural heritage elements with the stone carvings of the Six Steeds of Zhao Mausoleum. The sales of related digital collectibles and creative products have exceeded CNY2 million.

In addition to supporting cultural heritage preservation, BoGuan has been used to develop a range of cultural tourism apps, such as AI photography and AI travel companion agent. Visitors can directly talk with this agent on the GO-SHAANXI app to create and adjust travel itineraries and get real-time performance recommendations at attractions. The Zhiying Camera mini program provides paid services that instantly integrate user photos with AI-generated scenes from history, allowing visitors to "travel back to ancient times." These new consumption options unlock the business value of quality cultural tourism data. Furthermore, SCG is using BoGuan to integrate short drama production with cultural tourism and improve production efficiency and quality in Xi'an, a renowned short drama hub.

Additionally, China Telecom Shaanxi and Huawei have deployed a 5G-A network based on three component carrier aggregation (3CC) technology at Xi'an's Grand Tang Mall, a popular tourist attraction. The network delivers peak uplink and downlink rates of 600 Mbps and 3.5 Gbps, respectively, about 10 times faster than common 5G networks. During the 2026 May Day holiday, this network supported concurrent access for 23,000 users, guaranteeing smooth video watching and social media experiences. Furthermore, 5G-A-powered HD live streaming at the Grand Tang Mall has become an important way for the attraction to bring in new visitors. According to public data, the average user dwell time of these live streams has nearly doubled and the average transaction value has increased by 62%.

Edric Chu, General Manager of Huawei's Shaanxi Rep Office, giving a speech

Edric Chu, General Manager of Huawei's Shaanxi Rep Office, said, "Artificial intelligence is not simply a stack of technologies. It has become a key enabler that can activate thousands of years of cultural heritage, reshape travel experiences, and inject new momentum into the industry. Moving forward, Huawei will continue working with our partners to enhance cultural heritage preservation with digital and intelligent technologies, and stimulate development within the cultural tourism industry."

Hashtag: #Huawei

The issuer is solely responsible for the content of this announcement.

DFI Retail Group to Announce 2026 Half Year Financial Results and Host Analyst Presentation Live Webcast

Mon, 29 Jun 2026 20:00:22 +0700

HONG KONG SAR - Media OutReach Newswire - 29 June 2026 - DFI Retail Group Holdings Limited will announce its 2026 Half Year Results after market close on 28 July 2026, followed by an analyst presentation live webcast on 29 July 2026.

Date:	29 July 2026 (Wednesday)
Time:	09:30am – 10:30am (Hong Kong Time)
Presented by:	Scott Price, Group Chief Executive, and Tom van der Lee, Group Chief Financial Officer

Kindly RSVP by completing the form on or before Wednesday, 22 July 2026.

To avoid delays, we encourage participants to log in ten minutes ahead of the scheduled start time. A replay of the presentation will be available via webcast on DFI Retail Group's website.

Should you have any queries, please email us at DFIComms@DFIretailgroup.com.

Hashtag: #DFIRetailGroup #Mannings #Guardian #7-Eleven #Wellcome #MarketPlace #IKEA #yuu

The issuer is solely responsible for the content of this announcement.

About DFI Retail Group

DFI Retail Group is a leading Asian retailer driven by its purpose to 'Sustainably Serve Asia for Generations with Everyday Moments'. As at 31 December 2025, the Group and its associates operated 7,580 outlets and employed more than 79,000 people across 12 markets.

The Group is committed to delivering quality, value and service to consumers across the region through trusted brands, strong local market positions, and a broad retail ecosystem supported by extensive store networks, digital capabilities and efficient supply chains.

DFI Retail Group and its associates operate a portfolio of well-known brands across five key divisions: health and beauty, convenience, food, home furnishings and restaurants.

Shared Revitalization Journey of Weiqiao Pioneering Group, Weiqiao Town

Mon, 29 Jun 2026 20:00:21 +0700

BINZHOU, CHINA - Media OutReach Newswire - 29 June 2026 - Recently, Zouping, Shandong held a symposium on "Revitalizing Weiqiao Town," focusing on key priorities such as improving urban quality, upgrading public livelihoods, and empowering industrial development, laying out a clear blueprint for the high-quality development of Weiqiao Town.

Weiqiao Pioneering Group

"Weiqiao Town is the birthplace of Weiqiao Pioneering Group. Giving back to and building up our hometown remains our unwavering original aspiration," said Zhang Bo, Chairman of Weiqiao Pioneering Group, at a symposium on the "Revitalization of Weiqiao Town" on June 17.

Weiqiao National Institute of Science and Technology

Since the launch of the "Revitalization of Weiqiao Town" initiative in February 2025, Zouping City and Weiqiao Pioneering Group have worked hand in hand to drive the town's development. From January to May 2026, the town's gross industrial output value of industrial enterprises above the designated size grew by 6.97% year-on-year, while fixed-asset investment surged by 168.23%; total tax revenue and local-level fiscal revenue increased by 76.32% and 58.69%.

Leveraging the industrial chain resources and investment network of Weiqiao Pioneering Group, Weiqiao Town has attracted 28 industrial projects, of which 12 are now operational.

As the core engine of Zouping City's industrial economy, Weiqiao Pioneering Group adheres to the government-enterprise collaboration concept of "joint planning, shared industrial growth, and shared responsibility for public well-being." The Group has proactively opened up its upstream and downstream industrial chain, with 13 of the introduced projects serving as supporting facilities within its ecosystem. It has also reserved 300,000 tons of electrolytic aluminum production capacity to provide key support for extending, supplementing, and strengthening Weiqiao Town's aluminum industry chain.

Thirty years ago, the enterprise led the town to share the benefits of industrialization; thirty years later, its aspiration to repay the hometown remains unchanged. Through its Shiping Public Welfare Foundation, the Group has donated a total of RMB 186 million over the past two years to improve education, medical care, transportation, and other infrastructure, enhancing the people's sense of gain and happiness.

Together, Weiqiao Pioneering Group and Weiqiao Town are forging a revitalization path characterized by industrial prosperity, improved livelihoods, and rural beauty. Their partnership stands as a vivid example of the deep bond between an enterprise and its hometown, and of how mutual support can drive shared prosperity.

The issuer is solely responsible for the content of this announcement.